Application of Watson for Oncology in Hepatocellular Carcinoma Surgery

Liver Resection Clinical Trial

Official title:

Application of Watson for Oncology in Hepatocellular Carcinoma Surgery

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03904667
• Other study ID #: 20170101
• Status: Active, not recruiting
• Start date: January 1, 2017
• Est. completion date: December 31, 2021

Study information

• Verified date: January 2019
• Source: Zhujiang Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study was to evaluate the surgical decisions of Watson artificial intelligence in patients with hepatocellular carcinoma.

Description:

Hepatectomy is an effective treatment for patients with hepatocellular carcinoma, but liver failure after hepatectomy may lead to increased postoperative mortality. Therefore, it is very important to make preoperative surgical decisions, evaluate the safety of the operation and identify which patients are likely to suffer from liver failure. The artificial intelligence platform developed by IBM Watson for Watson tumor treatment decisions can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 150
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. 18 years= Age =80 years

2. Compling with the diagnosis criteria of complex hepatic carcinoma.

3. Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled

4. Preoperative liver function is Child - Pugh grade A or B.

5. The patients are volunteered for the study.

Exclusion Criteria:

1. Patients with mental illness.

2. Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.)

3. The patients refused to take part in the study.

4. There are other co-existed malignant tumors.

5. Benign liver diseases

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Liver Resection

Intervention

Other:
• Watson on oncology surgery decision evaluation
Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.

Locations

Country	Name	City	State
China	Zhujiang Hospital of Southern Medical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Disease-free survival	Survival time without tumor after hepatectomy	3 years
Primary	Operative outcomes	Operative outcomes such as operative time, estimated blood loss and blood transfusion were recorded.	intraoperative
Secondary	Postoperative survival	Survival after hepatectomy	3 years